Outstanding 12-month First-in-human Data from Xeltis’ aXess Hemodialysis Vascular Conduit Trial Presented at VEITHsymposium 2023
Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces outstanding 12-month data from its first-in-human (FIH) aXess vascular conduit trial (NCT04898153).…